Success Story: Pediatric Rheumatology Research Earns I-140 EB-1A Approval in 11 Days
Client’s Testimonial:
"I am truly grateful for all your hard work, guidance, and support throughout the preparation and filing of my EB-1A petition. I greatly appreciate the time and care your team invested in presenting my case, and I am delighted to learn that the petition has been approved. Thank you again for your professionalism, responsiveness, and assistance throughout this process. This approval is a very meaningful milestone for me and my family, and I sincerely appreciate your contribution to this achievement.”
On June 9th, 2026, we received another EB-1A (Alien of Extraordinary Ability) approval for a Postdoctoral Researcher in the Field of Pediatric Rheumatology (Approval Notice).
General Field: Pediatric Rheumatology
Position at the Time of Case Filing: Postdoctoral Researcher
Country of Origin: Turkey
Approval Notice Date: June 9th, 2026
Processing Time: 11 days (Premium Processing Requested)
Case Summary:
The client earned a master’s degree and an M.D. degree, building an influential career in pediatric rheumatology with a focused record in inflammatory diseases. Her work centers on advancing the understanding, diagnosis, and management of autoinflammatory and autoimmune diseases. The petition framed this work as especially important because improved knowledge of rare pediatric inflammatory diseases can support earlier diagnosis, more precise treatment strategies, and stronger clinical decision-making.
Rather than presenting the client’s work as only a publication record, the petition emphasized how her research had shaped the field’s approach to disease classification, genetic screening, biomarker identification, and treatment planning. Her current work at a leading U.S. biomedical research institution continues this trajectory through research into the genetic and molecular mechanisms underlying systemic autoinflammatory and autoimmune diseases.
The client’s record included 195 peer-reviewed journal articles, including 60 first-authored or co-first-authored articles, 35 conference abstracts, 8 book chapters, 5,246 citations, and at least 587 peer reviews. The petition did not treat these metrics as automatically sufficient. Instead, it explained that the publication record reflected sustained scholarly production, the citation count showed broad independent reliance on her findings, and the peer-review activity demonstrated that journals and research venues repeatedly trusted her expertise to evaluate the work of other specialists.
Independent researchers had relied on the client’s work to study monogenic lupus, kidney disease pathologies, and pediatric autoimmune disease mechanisms. North America Immigration Law Group connected these examples to show that her findings were not isolated academic contributions, but had become part of the field’s broader foundation for understanding rare inflammatory diseases and developing more precise clinical strategies.
The case was also supported by 4 letters of recommendation from experts in the field, including independent experts familiar with the client’s work through her publications and research influence. Their letters helped explain the significance of her contributions in practical and field-specific terms, confirming how her research had informed later studies and strengthened pediatric rheumatology.
With direct premium processing requested at the time of filing, the client’s I-140 EB-1A petition was approved in 11 days. This approval reflects the successful presentation of a case grounded in pediatric rheumatology expertise, sustained peer recognition, extensive independent reliance, and the prospective benefit of continued research on autoinflammatory and autoimmune diseases in the United States.